A closed-loop cell therapy engineered to autonomously secrete Activin A inhibitor protects from fibrodysplasia ossificans progressiva
This study demonstrates that a closed-loop cell therapy, engineered to autonomously secrete an Activin A inhibitor (ActR2A-Fc) in response to Activin A exposure via a BMP-responsive promoter, effectively prevents heterotopic bone formation in a mouse model of fibrodysplasia ossificans progressiva (FOP).